Katelyn Rourk

Ms. Katelyn Rourk

Mayo Clinic, Rochester, Indiana, USA
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2025 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
KRKatelyn Rourk
Katelyn Rourk
GDGhazal S. Daher
Ghazal S. Daher
JSJenna R. Schwartz
Jenna R. Schwartz
HAHawa M. Ali
Hawa M. Ali
ASAnne K. Shurtz
Anne K. Shurtz
EMEric J. Moore
Eric J. Moore

25 May 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
ASArashdeep Singh
Arashdeep Singh
KRKatelyn Rourk
Katelyn Rourk
ABAngelina VALLADARES Bernier
Angelina VALLADARES Bernier
GLGuillaume de Lartigue
Guillaume de Lartigue
Metformin, a frontline therapy for type 2 diabetes and related metabolic diseases, results in variable outcomes. This study aimed to investigate whether sweetened beverages (caloric or non-caloric) affect the therapeutic benefits of metformin on glucose, food intake, and weight loss in diet-induced obesity. Mice were given a high-fat diet and sweetened water for 8 weeks to induce obesity and glucose intolerance. Then, mice were randomized to receive metformin in either water, high-fructose corn syrup (HFCS), or the non-nutritive sweetener saccharin for 6 weeks. After 6 weeks of metformin treatment, all groups had improved glucose tolerance compared to pretreatment. However, saccharin resulted in worse glucose tolerance and weight gain outcomes than the water or HFCS groups and correlated with lower plasma growth differentiation factor 15 levels. In conclusion, reducing non-nutritive sweetener consumption during metformin therapy is recommended to avoid impairing the therapeutic effects of metformin on body weight and glucose homeostasis.

21 May 2025 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
KRKatelyn Rourk
Katelyn Rourk
GCGabriela A. Calcano
Gabriela A. Calcano
HAHawa M. Ali
Hawa M. Ali
AGAmy E. Glasgow
Amy E. Glasgow
EHElizabeth B. Habermann
Elizabeth B. Habermann
LYLinda X. Yin
Linda X. Yin

11 February 2025 in Oral Oncology Reports
Verified
Journal Article
Open access
DMDante Merlino
Dante Merlino
KRKatelyn Rourk
Katelyn Rourk
GSGeorge B. Sankar
George B. Sankar
ALAdam J. Luginbuhl
Adam J. Luginbuhl
BBBrian J. Boyce
Brian J. Boyce
KAKathryn M Van Abel
Kathryn M Van Abel

18 May 2026 in Annals of Otology, Rhinology & Laryngology
Verified
Journal Article
Closed access
KRKatelyn Rourk
Katelyn Rourk
CHCecelia M. Hidalgo
Cecelia M. Hidalgo
ASAnne K. Shurtz
Anne K. Shurtz
KTKendall K. Tasche
Kendall K. Tasche
DPDaniel L. Price
Daniel L. Price
EMEric J. Moore
Eric J. Moore
Objective(s): To (1) report on the long-term recurrence rate of surgically managed pleomorphic adenoma (PA) and (2) assess long-term surgical outcomes after parotidectomy Methods: Cross-sectional survey of all patients with a pathologic diagnosis of PA who underwent surgical management in a tertiary care center from 01/1997 to 12/2023 and had access to an electronic patient portal. Surveys were delivered via electronic patient portal or phone call with 6 questions to assess recurrence and long-term surgical outcomes. Time to first recurrence and recurrence free survival were analyzed using a Kaplan-Meier curve. Results: Seven hundred-forty-five patients met inclusion criteria and received the survey, with a 56% response rate (n = 420). The clinical median follow-up length was 51 days, which extended to a median length of 6.2 years following the survey. The median change in follow-up length was 5.37 years ( P < .001). The recurrence rate was 1% at 5 years, with a median time to first recurrence of 7.54 years. 13% and 9% of responders reported facial asymmetry and incisional cosmetic concerns, respectively. 33% of patients reported experiencing Frey syndrome, which increased from 5.2% of survey responders with documented Frey syndrome at their original post-operative assessment. Conclusion: Long-term assessment of PA outcomes confirms low recurrence rates, suggesting regular surveillance of recurrence is likely unnecessary. Complaints of Frey syndrome increased in frequency with longer term follow-up, which should be considered during patient counseling. Level of Evidence: 3